Page 40 - GHES-3-3
P. 40

Global Health Economics and
            Sustainability
                                                                                Semaglutide for treating T2D and obesity


            Tamhane,  S., Rodriguez-Gutierrez,  R., Hargraves, I.,  &      https://doi.org/10.3390/ijms24076192
               Montori, V.M. (2015). Shared decision-making in diabetes   Wu, S., Lu, W., Chen, Z., Dai, Y., Chen, K., & Zhang, S. (2022).
               care. Current Diabetes Reports, 15(12):112.
                                                                  Association of glucagon-like peptide-1 receptor agonists
               https://doi.org/10.1007/s11892-015-0688-0          with cardiac arrhythmias in patients with type  2 diabetes
                                                                  or obesity: A  systematic review and meta-analysis of
            Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., &
               Tentolouris, N. (2019). SGLT2 Inhibitors: A review of their   randomized controlled trials.  Diabetology and Metabolic
               antidiabetic and  cardioprotective  effects.  International   Syndrome, 14(1):195.
               Journal  of  Environmental  Research  and  Public  Health,      https://doi.org/10.1186/s13098-022-00970-2
               16(16):2965.
                                                               Xie,  Z.,  Li,  J.,  Yang,  S.,  Deng,  W.,  &  Chen,  J.  (2022).  A  health
               https://doi.org/10.3390/ijerph16162965             technology assessment based on Chinese guidelines:
                                                                  glucagon-like  peptide-1  receptor  agonist in  the  treatment
            Turchetti, G., Spadoni, E., & Geisler, E. (2010). Health Technology
               Assessment. Available from:    https://ie e explore.  of type 2 diabetes complicated with cardiovascular disease.
               ieee.org/abstract/document/5463009 [Last accessed on   Therapeutics and Clinical Risk Management, 18:889-900.
               2018 Apr 11].                                      https://doi.org/10.2147/TCRM.S375067
            Uzoigwe, C.,  Liang, Y., Whitmire, S., & Paprocki, Y. (2021).   Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022). Efficacy and
               Semaglutide once-weekly persistence and adherence versus   safety of liraglutide and semaglutide on weight loss in people
               other GLP-1 RAs in patients with type 2 diabetes in a US   with obesity or overweight: A  systematic review.  Clinical
               real-world setting. Diabetes Therapy, 12(5):1475-1489.  Epidemiology, 14:1463-1476.
               https://doi.org/10.1007/s13300-021-01053-7         https://doi.org/10.2147/CLEP.S391819
            Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L.J.,   Yuan, X., Gao, Z., Yang, C., Duan, K., Ren, L., & Song, G. (2023).
               Davitkov, P.,  et  al. (2021). Association of glucagon-like   Comparing the effectiveness of long-term use of daily and
               peptide 1 analogs and agonists administered for obesity   weekly glucagon-like peptide-1 receptor agonists treatments
               with  weight  loss  and  adverse  events:  A  systematic review   in patients with nonalcoholic fatty liver disease and type 2
               and network meta-analysis. EClinicalMedicine, 42:101213.  diabetes mellitus: A  network meta-analysis.  Frontiers in
                                                                  Endocrinology (Lausanne), 14:1170881.
               https://doi.org/10.1016/j.eclinm.2021.101213
                                                                  https://doi.org/10.3389/fendo.2023.1170881
            Weeda, E.R., Muraoka,  A.K.,  Brock,  M.D.,  & Cannon,  J.M.
               (2021). Medication adherence to injectable glucagon-like   Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., et al.
               peptide-1 (GLP-1) receptor agonists dosed once weekly vs   (2023). GLP-1RAs caused gastrointestinal adverse reactions
               once daily in patients with type 2 diabetes: A meta-analysis.   of drug withdrawal: A  system review and network meta-
               International Journal of Clinical Practice, 75(9):e14060.  analysis. Frontiers in Endocrinology (Lausanne), 14:1149328.
               https://doi.org/10.1111/ijcp.14060                 https://doi.org/10.3389/fendo.2023.1149328
            Weiss, T., Carr, R.D., Pal, S., Yang, L., Sawhney, B.,   Zhu, J., Zhou, Y., Li, Q., & Wang, G. (2023). Cost-effectiveness
               Boggs, R.,  et al. (2020). Real-world adherence and   of newer antidiabetic drugs as second-line treatment for
               discontinuation of glucagon-like peptide-1 receptor agonists   type 2 diabetes: A systematic review. Advances in Therapy,
               therapy in type 2 diabetes mellitus patients in the United   40(10):4216-4235.
               States. Patient Prefer Adherence, 14:2337-2345.
                                                                  https://doi.org/10.1007/s12325-023-02612-z
               https://doi.org/10.2147/PPA.S277676
                                                               World Obesity Federation. Obesity: Missing the 2025 global targets.
            Wilson, R.B., Lathigara, D., & Kaushal, D. (2023). Systematic   Trends, Costs and CountryReports. (2020).  Available from:
               review and meta-analysis of the impact of bariatric surgery   https://s3-eu-west-1.amazonaws.com/wof-files/970_-_
               on future cancer  risk.  International Journal of Molecular   WOF_Missing_the_2025_Global_Targets_Report_ART.pdf
               Sciences, 24(7):6192.                              [Last accessed on 2025 Mar 18].

















            Volume 3 Issue 3 (2025)                         32                       https://doi.org/10.36922/ghes.8547
   35   36   37   38   39   40   41   42   43   44   45